Please login first

Pharmaceuticals Webinar | Cardio-Oncology: From Adverse Outcome Pathways to Cardiotoxicity Mitigation

Part of the Pharmaceuticals Webinar series
7 Dec 2022, 11:00 (CET)

Cardiooncology, Cardiotoxicity, Mitochondria, Topoisomerase IIbeta, Iron Chelation, Treatment, Doxorubicin, Mitoxantrone
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chair

1st Pharmaceuticals Webinar

Cardio-Oncology: From Adverse Outcome Pathways to Cardiotoxicity Mitigation

The efficacy of anticancer therapies together with early diagnosis has successfully decreased cancer death rates, warranting a longer life to cancer patients. Thus, at present, surviving cancer is not enough and a new meaning has been given to the sentence ‘life after cancer’.

Actually, the quality of life and the full integration of survivors back to society is a new concern amongst the clinical and scientific community. Nevertheless, the adverse effects of anticancer treatments bring a huge burden to patients and health systems.

Cardiotoxicity of anticancer therapies is the second leading cause of death amongst cancer survivors. This adverse effect has been detected in patients since the early use of chemotherapy. Back then, a new field in cardiology, called ‘cardio-oncology’ emerged. Although in the beginning, cardio-oncology aimed to address only the cardiotoxicity of chemotherapy and radiotherapy, at present it focuses on the detection, monitoring, and treatment of cardiovascular disease after classic treatments and also molecular-targeted agents and immune-modulating agents. The ultimate goal is to provide curative or preventive treatment to the cardiovascular complications that arise with cancer treatment without compromising anticancer drug efficacy.

This webinar aims to focus on the adverse outcome pathways of several anticancer treatments and present new pharmacological alternatives that can prevent or cure the cardiotoxicity elicited by anticancer treatments.

Date: 7 December 2022

Time: 11:00 am CET | 5:00 am EST | 6:00 pm CST Asia

Webinar ID: 848 1041 4835

Webinar Secretariat:


ICETA, Toxicology Laboratory, Faculty of Pharmacy, University of Porto, Portugal

Vera Marisa Costa (VMC) is a Researcher at the Faculty of Pharmacy University of Porto (FFUP), integrated at the excellence center UCIBIO\REQUIMTE. VMC is a Pharmacist with a PhD on Toxicology attributed in 2009 by the Faculty of Pharmacy University of Porto, being the thesis in the field of cardiotoxicity of catecholamines. At present, she holds 100+ international papers in peer-reviewed international journals (Scopus h-index of 34), 2 articles in national journals, and 4 book chapters. Her works impacts in Medical and Health Sciences with emphasis on Pharmacology, Pharmacy and Toxicology, mainly focusing on Onco-Cardiology, Chemobrain and Toxin Toxicity. She was the Principal Investigator on two FCT-funded projects (‘Why is mitoxantrone a poison to the heart? Focus on mitochondria, cytoskeleton, and metabolic bioactivation mechanisms’ and ‘Poisoning the heart with anticancer drugs: is metabolic bioactivation or aging promotion the link to the cardiotoxicity of anticancer drugs?’), being participant in 5 funded national projects and one EU-funded pedagogic project. She is (co)supervisor of 5 PhD students, being co-supervisor of 3 finalized PhD. She has (co)supervised 12 MSc dissertation(s) (plus 4 are ongoing). VMC has pedagogic experience in the Faculties of Pharmacy and Medicine in the University of Porto, CESPU and University of Trás-os-Montes and Alto Douro in the fields of Toxicology, Occupational Medicine and Pharmacology. She is Associated Editor in three international peer-reviewed scientific journals on Pharmaceutical Sciences and Toxicology. In recent years, she has been a Scientific Evaluator of research projects applied for funding on Italy, Poland, Romania and Serbia Scientific Programs and member of several COST actions, with focus on cardiac health.

Invited Speakers

Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Czech Republic

Associate Professor of Pharmacology, Deputy Head of the Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. Team Leader and Principal Investigator of CardioTox In Vivo research laboratory at Faculty of Medicine in Hradec Králové. Associate Editor of ESC Heart Failure and Cardiovascular Toxicology. Research focus: cardiovascular toxicity of anticancer drugs (particularly anthracycline cardiotoxicity), pharmacological cardioprotection and heart failure research. Education: MSc. in Pharmacy/PharmD. (2002/2007) – Pharmaceutical Faculty in Hradec Králové, Charles University and PhD. in Medical Pharmacology (2007) – Faculty of Medicine in Hradec Králové, Charles University.

MitoXT - Mitochondrial Toxicology and Experimental Therapeutics Laboratory, CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal

Paulo J. Oliveira is currently Principal Investigator with “Agregação” (Habilitation) at the CNC – Center for Neuroscience and Cell Biology, University of Coimbra, Portugal. He is the current leader of the “Mitochondria, Metabolism and Disease” group and of the MitoXT: Mitochondrial Toxicology and Experimental Therapeutics laboratory. He received his Bachelor of Science in Biochemistry from the University de Coimbra in 1999. In 2003, he completed his PhD in Cellular Biology from the same University. After completing his doctorate, Paulo Oliveira spent more than three years working at the University of Minnesota Medical School, Duluth, USA, where he collaborated with several researchers and contributed to the publication of several peer-reviewed manuscripts. Paulo Oliveira's current research focuses on mitochondrial biology, investigating the alteration of cardiac mitochondrial function by physical activity and diet, cardiac mitochondrial dysfunction and cell death caused by anti-neoplastic agents, mitochondrial alterations during cancer stem cell differentiation and carcinogenesis or rational designing and validation of mitochondria-directed antioxidants. Paulo has over 280 peer-reviewed publications and many collaborations in Europe, Africa, and the USA. He has also received several prizes from the Portuguese Cardiology Society for his work on cardiac mitochondrial research. Besides research, Paulo Oliveira is often involved in teaching at the Department of Life Sciences, University of Coimbra, as well as in other Universities in Portugal and elsewhere, besides in numerous science communication activities. Paulo Oliveira has also been a reviewer for more than 40 scientific journals and over 10 different funding agencies, including the European Commission (Research Executive Agency) and the Portuguese Foundation for Science and Technology. His research group is supported by competitive national and international funding agencies, including the Portuguese Foundation for Science and Technology, the European Commission, and private foundations.

Webinar Content

To view this content, you need to be registered and logged in to Sciforum platform.



Time in CET

Dr. Vera Marisa Costa

Chair Introduction

11:00 - 11:10 am

Dr. Vera Marisa Costa

Cardio-Oncology: For Old or New Drugs, the Problem (Cardiotoxicity) Remains After Cancer Treatment

11:10 - 11:40 am

Dr. Martin Štěrba

Pharmacological Protection Against Anthracycline Cardiotoxicity Using Dexrazoxane and Other Bisdioxopiperazines: From Iron Chelation to Topoisomerase Iibeta and Beyond

11:40 am - 12:10 pm

Dr. Paulo J. Oliveira

Doxorubicin-Induced Cardiomyopathy: From Mitochondria to Clocks

12:10 - 12:40 pm

Q&A Session

12:40 - 12:55 pm

Closing of Webinar
Dr. Vera Marisa Costa

12:55 - 1:00 pm

Relevant SI

Current Frames on Cardiotoxicology of New and Old Anticancer Drugs
Guest Editor: Prof. Dr. Vera Marisa Costa
Deadline for manuscript submissions: 31 May 2023

Sponsors and Partners